Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2013-02-18 Capital/Financing Update
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2013
Capital/Financing Update Classification · 99% confidence The document is a formal announcement from Blue Vision A/S, titled 'SELSKABSMEDDELELSE' (Company Announcement). It details a significant financial event: entering into a loan agreement (låneaftale) of up to DKK 16,500,000 to settle an existing banking engagement with Nykredit and address liquidity challenges. This type of announcement, concerning financing, capital structure adjustments, or significant debt restructuring, directly aligns with the definition of 'Capital/Financing Update'. The document is short and serves as an immediate notification of a financial transaction, not a comprehensive report. Therefore, the most appropriate code is CAP.
2013-02-18 English
Capital/Financing Update 2013
Capital/Financing Update Classification · 99% confidence The document is a formal announcement dated February 18, 2013, detailing a significant financial arrangement: Blue Vision A/S securing a loan facility of up to DKK 16,500,000 from Ejby Industrivej, Glostrup ApS to settle obligations related to a terminated agreement with Nykredit Bank A/S. This involves changes to the company's financing structure and liquidity management. This clearly falls under updates regarding company fundraising, financing activities, or capital structure changes, matching the definition for Capital/Financing Update (CAP). It is not an earnings release, an annual report, or a management discussion, but a specific corporate finance action announcement.
2013-02-18 Danish
Legal Proceedings Report 2013
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement dated January 18, 2013, titled 'Likviditetsmæssige udfordringer' (Liquidity challenges). It discusses specific financing arrangements (a responsible loan from DOXA Investments A/S), restrictions on the use of proceeds, and ongoing negotiations related to subsidiary debt and shareholder notes (ALMC's vendor notes). The core subject is the company's ability to secure necessary liquidity for continued daily operations and the uncertainty regarding its going concern status. This content directly relates to updates on the company's financial structure, funding issues, and potential solvency concerns, which aligns best with the 'Capital/Financing Update' category, as it details issues with existing capital/debt instruments and immediate funding needs. It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV).
2013-01-18 Danish
Legal Proceedings Report 2013
Legal Proceedings Report Classification · 99% confidence The document is a short official announcement from Blue Vision A/S, titled 'SELSKABSMEDDELELSE' (Company Announcement), dated January 18, 2013. The content discusses liquidity challenges ('Likviditetsmæssige udfordringer'), issues related to a responsible loan, negotiations with banks, and uncertainty regarding the company's ability to continue as a going concern. This type of urgent, material, non-periodic disclosure regarding financial stability or significant operational hurdles, often related to financing or debt covenants, fits best under a general regulatory announcement category. Since it is not a formal financial report (10-K, IR), an earnings release (ER), or a specific management/board change, it falls under the general regulatory filing category, RNS, as it is a material event disclosure.
2013-01-18 English
Legal Proceedings Report 2013
Legal Proceedings Report Classification · 99% confidence The document is a short announcement (974 characters) from Blue Vision A/S, dated January 17, 2013, updating stakeholders on ongoing negotiations with Nykredit Bank A/S regarding a terminated framework agreement. It explicitly states that the management 'can hereby announce' (kan hermed meddele) that negotiations are continuing and have been extended by 30 days. This is a general corporate update regarding a financial/legal matter (the termination of a bank agreement and subsequent negotiations) that does not fit the specific categories like ER, 10-K, or DIV. Since it is a short, specific update on an ongoing corporate event, and it doesn't announce the publication of a larger report, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory announcement, or potentially LTR if the dispute was more adversarial, but RNS is the safer fallback for general corporate news updates not covered elsewhere.
2013-01-17 Danish
Legal Proceedings Report 2013
Legal Proceedings Report Classification · 99% confidence The document is a short announcement (1104 characters) dated January 3, 2013, from Blue Vision A/S regarding an ongoing dispute and negotiation with Nykredit Bank A/S concerning the termination of a framework agreement and the inability of a subsidiary (Seaside Holding A/S) to cover negative market value of interest rate swaps. It explicitly states that the company will 'løbende orientere markedet om udviklingen i forhandlingerne' (continuously inform the market about the development in the negotiations). This content relates to significant legal/financial disputes and ongoing negotiations that affect the company's financial standing and obligations. It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it details a significant legal/financial matter and ongoing negotiations, it fits best under Legal Proceedings Report (LTR) or potentially a general Regulatory Filing (RNS). Given the focus on the legal justification of a termination and ongoing negotiations over financial instruments (interest rate swaps), LTR is the most specific fit, although it could also be considered a general regulatory update.
2013-01-03 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.